Inhibiting BRAF signaling has been demonstrated to reduce myeloid-derived suppressor cells, increase the recruitment of tumor-infiltrating lymphocytes, enhance neoantigen presentation on antigen-presenting cells, and collectively enhance anti-tumor immune responses (28, 30–32). Here, BRAF is linked to neoplasm.